At the 2024 European Society for Medical Oncology (ESMO) Congress, Kangfang Biotech (HKG: 9926) debuted its independently developed PD-1/VEGF bispecific antibody, Yivoxi, in combination with or without the next-generation CD47 monoclonal antibody, Laifali, plus FOLFOXIRI as a first-line treatment for microsatellite stable (MSS) or proficient mismatch repair (pMMR) advanced metastatic colorectal cancer (mCRC). Professor Deng Yanhong from the Sixth Affiliated Hospital of Sun Yat-sen University, the lead researcher of the study, presented an oral report at the event.
Known as ‘immunological deserts,’ MSS/pMMR mCRC tumors have historically shown limited benefits from immunotherapies, with the clinical standard first-line treatment remaining chemotherapy combined with bevacizumab or cetuximab, which offers very limited efficacy.
Preliminary clinical study results indicate that the combination of Yivoxi with or without Laifali and FOLFOXIRI as a first-line treatment for MSS/pMMR mCRC holds groundbreaking clinical value and has the potential to fill the immunotherapy gap for these patients.
As of February 29, 2024, the median follow-up time for the Yivoxi plus Laifali plus FOLFOXIRI group was 9.6 months, and for the Yivoxi plus FOLFOXIRI group, it was 9.0 months. – Flcube.com
